Injection weight loss drugs such as Zepbound and Mounjaro have dominated the market, but weight-loss pills could soon hit the market. (Brendan McDermid/George Frey/Reuters)

By Daniel Gilbert

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will patients embrace a more convenient alternative to injecting themselves, even if it means losing less weight?

Eli Lilly said Thursday it will seek regulatory approval for its experimental weight-loss pill by the end of the year, announcing results from its latest clinical trial that, while positive, did not appear to be as potent as injectable anti-obesity medications. PAID PROMOTED STORIES

See Full Page